Nuclear Cardiology Software for Image Processing & Quantification

Artificial Intelligence in Medicine

The Artificial Intelligence in Medicine (AIM) program is a Nuclear Cardiology Software for processing and archiving that has established itself as the gold standard among users. AIM a research program of the Department of Medicine at Cedars-Sinai Medical Center – one of the largest non-profit hospitals with thousands of healthcare professionals including 2100+ physicians, 2800+ nurses and researchers

Quantitative Gated SPECT

Over the years, AIM has become the most validated nuclear cardiology software package for imaging. It is also USFDA approved & CE marked in Europe. AIM adds a layer of analysis via features & modules that are unique – providing analysis and processing of 3D images of the heart.

How AIM Works

AIM can operate independent of human intervention, is easy to use and accessible, and has resulted in in improved outcomes, particularly for high risk people without symptoms, such as those with diabetes.

Changing lifestyles, increasing longevity and other risk factors such as hypertension, diabetes, hyperlipidaemia or already established disease) mean CVD causes more deaths than any other cause – becoming the leading cause of fatalities across the world – responsible for over 17million deaths annually. With an increasing patient base, AIM is finding increased use/application growing applications across the ever increasing number of nuclear medicine centers across the globe.

Global populations are in need of early detection mechanisms, personalized management using counselling and medicines and advanced analysis. While traditional methods have been relied upon for years, the interpretation of the results in a more meaningful manner can now be achieved through software like AIM through:

• Highly accurate interpretation of cardiac health
• Timely intervention through rapid results
• Little to no intervention from cardiologists during analysis
• Patient records & management

AIM is now available for commercially available for more information & enquiries – click here